1832 Asset Management
ARCT icon

1832 Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

1832 Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-560
Closed -$4K – 691
2019
Q1 		$4K Hold
560
– – ﹤0.01% 601
2018
Q4 		$3K Hold
560
– – ﹤0.01% 600
2018
Q3 		$5K Hold
560
– – ﹤0.01% 611
2018
Q2 		$5K Buy
+560
New +$3.63K ﹤0.01% 601

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

1832 Asset Management's ARCT Position: Q2 2019 in Review

1832 Asset Management sold out of Arcturus Therapeutics (ARCT) in Q2 2019, closing a stake of 560 shares — an estimated $4K sold.

1832 Asset Management first reported a position in ARCT in Q2 2018 and held it in 4 quarters. The position peaked at $5K in Q3 2018. 23 funds tracked by Wall St. Rank hold ARCT as of Q2 2019.

  • 1832 Asset Management reported no remaining Arcturus Therapeutics position as of Q2 2019 after selling out during the quarter.
  • 1832 Asset Management sold 560 Arcturus Therapeutics shares in Q2 2019, an estimated $4K.
  • 1832 Asset Management first reported a position in Arcturus Therapeutics in Q2 2018 and held it in 4 quarters.
  • 1832 Asset Management's Arcturus Therapeutics position peaked at $5K in Q3 2018.
  • 23 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2019.

Based on 1832 Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.